YOLFTbeta
18

EyeGene Inc

185490 · KQ · Healthcare / Biotechnology

1,718.00KRW-37.00 (-2.11%)

Price History

Full chart

Market Stats

Previous Close1,755.00
Open1,779.00
Day Range1,715.00 – 1,812.00
52-Week Range1,182.00 – 2,805.00
Volume39.09K
Market Cap82.34B
P/E (TTM)0.00
Forward P/E0.00
Dividend Yield0.00%
Beta0.75
50-Day Avg1,850.98
200-Day Avg1,591.26

About

EyeGene Inc. engages in the research and development of biopharmaceutical drugs for the treatment and prevention of age-related diseases in South Korea. Its product pipeline comprises EG-Mirotin, which has completed Phase 2a clinical trial to treat diabetic retinopathy; EG-Decorin which completed Phase 2 clinical trial for the treatment of pressure ulcers and wound healing; and EG-Myocin, which has completed Phase II clinical trials for the treatment of myocardial ischemia/reperfusion injury. It also develops EG-HZ, which has completed phase 1 clinical trial for the treatment of herpes zoster; EG-HPV which completed Phase 1 clinical trial to treat cervical cancer; EG-COVID that is in phase I clinical trial for the treatment of covid; and EG-TB for the tuberculosis vaccine and is in preclinical trial. In addition, the company offers vitalDB for beautiful vitality. EyeGene Inc. was founded in 2000 and is headquartered in Seoul, South Korea.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Won-Il Yoo
  • Employees47
  • Headquarters401 Yangcheon-ro, Seoul, South Korea, 16009, Korea
  • Websitehttps://www.eyegene.co.kr

Leadership

  • Mr. Won-Il YooChief Executive Officer
  • Dr. Yang-Je ChoCo-Founder and Chief Technology Officer
  • Soobeom LeeChief Financial Officer

Financials

Income Statement

Currency: KRW2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue153.79M107.56M267.23M301.03M2.04B4.25B3.36B3.24B5.29B3.13B3.36B3.57B
Growth (%)--30.06%+148.45%+12.65%+576.10%+108.59%-20.77%-3.61%+63.27%-40.96%+7.37%+6.29%
Cost of Revenue12.67M14.69M68.58M203.67M1.27B2.31B1.81B1.74B2.55B1.24B2.20B2.45B
Gross Profit141.12M92.87M198.66M97.36M761.94M1.94B1.55B1.50B2.75B1.89B1.16B1.12B
Gross Margin91.76%86.34%74.34%32.34%37.44%45.64%46.18%46.40%51.88%60.38%34.50%31.28%
Operating Expense3.21B5.28B8.79B9.39B9.03B11.50B15.57B38.37B26.38B29.05B14.41B10.97B
Operating Income-3.07B-5.19B-8.59B-9.29B-8.27B-9.56B-14.02B-36.86B-23.63B-27.16B-13.25B-9.85B
Operating Margin-1997.31%-4823.92%-3214.71%-3086.98%-406.13%-225.25%-416.71%-1136.97%-446.43%-869.13%-394.95%-276.18%
EBITDA---------25.97B-19.83B-9.85B-16.37B
EBITDA Margin---------490.63%-634.51%-293.64%-458.98%
Net Income-2.93B-4.90B-8.27B-8.45B-5.91B-8.74B-14.86B-34.57B-25.95B-21.11B-12.13B-15.71B
Net Income Margin-1902.44%-4552.80%-3094.59%-2807.29%-290.27%-205.88%-441.90%-1066.25%-490.29%-675.30%-361.41%-440.34%
R&D1.65B2.65B4.69B5.05B3.78B5.10B8.82B27.99B16.34B20.36B8.27B5.92B
R&D as % of Total Revenue1070.16%2459.42%1754.87%1677.35%185.88%120.02%262.33%863.46%308.75%651.54%246.32%166.04%
Interest Expense0000002.52B1.75B395.32M462.60M699.01M628.63M
Interest Expense % of Total Revenue0.00%0.00%0.00%0.00%0.00%0.00%74.85%54.11%7.47%14.80%20.83%17.62%

Balance Sheet

Currency: KRW2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets5.54B24.33B18.56B30.28B54.04B47.31B44.43B104.99B80.38B78.10B65.31B68.05B
Total Liabilities1.69B1.57B2.37B6.53B30.70B28.28B31.53B16.02B13.65B13.77B14.98B13.80B
Total Equity3.85B22.76B16.19B23.75B23.34B19.03B12.90B88.97B66.73B63.23B50.32B57.13B
Cash2.58B2.29B651.33M1.60B151.09M2.01B1.52B1.61B764.31M5.50B863.97M10.19B
Total Debt---3.79B22.18B2.87B11.66B-----
Net Debt-----11.23B12.45B345.43M--348.03M-

Cash Flow

Currency: KRW2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-2.39B-4.48B-5.99B-6.76B-7.48B-8.32B-9.75B-30.00B-18.57B-20.07B-12.17B-5.98B
Investing Cash Flow3.03B-15.45B615.95M-8.28B-26.96B11.07B4.45B-56.68B17.25B5.67B7.34B-
Financing Cash Flow1.68B23.21B288.26M18.66B30.72B403.13M4.14B86.62B879.97M17.85B646.52M-
Capital Expenditure352.08M129.13M1.49B272.70M243.35M990.94M2.03B2.38B767.86M1.67B4.99B1.22B
Free Cash Flow-------11.84B-32.83B-19.47B-21.79B-17.16B-7.20B
FCF to OCF------121.42%109.42%104.88%108.58%140.97%120.45%

Earnings

Report DateMay 13, 2016Aug 9, 2016Nov 14, 2016Feb 10, 2017May 11, 2017Aug 11, 2017Nov 14, 2017Mar 15, 2018May 15, 2018Aug 14, 2018Nov 14, 2018Feb 13, 2019May 15, 2019Aug 23, 2019Nov 14, 2019Feb 24, 2020May 15, 2020Aug 14, 2020Nov 16, 2020Feb 24, 2021Mar 31, 2021Dec 31, 2021Mar 31, 2022Jun 30, 2022Sep 30, 2022Dec 31, 2022Mar 31, 2023Jun 30, 2023Sep 30, 2023Feb 20, 2024Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
EPS Estimate----------------------------------------
EPS Actual-80.97-165.05-178.22-205.66-170.39-174.96-165.20-120.05-193.82-115.34-53.23-48.74-210.00-192.74-22.06-270.69-262.29-162.98-269.11-285.56-181.08-962.61-253.64-422.41-212.51-147.61-301.56-288.27-61.60-176.03-97.19-93.79-104.56-88.49-93.04-76.54-48.01-307.40-79.85-86.78
Surprise----------------------------------------
TimingAfter-hoursPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-market---------Pre-market----------

Key Statistics & Ratios

Market Cap82.34B
Enterprise Value46.12B
Trailing P/E0.00
Forward P/E0.00
Price / Sales18.37
Price / Book1.68
Revenue (TTM)4.48B
Gross Profit (TTM)1.20B
EBITDA-10.49B
Profit Margin0.00%
Operating Margin-294.76%
Return on Equity-43.53%
Return on Assets-12.77%
Shares Outstanding43.22M
Shares Float30.30M
Beta0.75
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Stock Splits

  • Oct 24, 20254114:3521
  • Jun 28, 20216:5
  • May 13, 20211091:1000